Form 4: Privia Health CFO Sells Shares Under 10b5-1 Plan

Privia Health Group, Inc. EVP & Chief Financial Officer David Mountcastle reported a sale of 600 shares of common stock, executed under a pre-arranged 10b5-1 trading plan.

Summary

• David Mountcastle, EVP & Chief Financial Officer of Privia Health Group, Inc., sold 600 shares of common stock on July 7, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan, which is designed to comply with SEC safe harbor provisions for insider trading.
• The shares were sold at a weighted average price of $27.57, with individual transactions ranging from $27.55 to $27.58.
• Following this transaction, Mountcastle beneficially owns 186,128 shares directly and 8,695 shares indirectly through his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves an insider sale, the execution under a Rule 10b5-1 plan suggests a pre-determined, non-opportunistic transaction, thus not indicating strong positive or negative sentiment about the company's prospects.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, although the plan's existence mitigates concerns about opportunistic trading.

Risks

• The primary risk associated with this filing is the market's interpretation of insider selling, which could lead to short-term negative sentiment towards the stock, despite the structured nature of the sale.

Future Outlook

This filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common practice in the healthcare services industry to manage personal stock portfolios while adhering to insider trading regulations. This filing indicates standard operational procedures for executive compensation and liquidity management within the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale by a key executive might lead to short-term market scrutiny, but the 10b5-1 plan structure aims to prevent adverse impacts related to insider trading perceptions.
• Employees: No direct impact is indicated for employees.
• Creditors: No direct impact is indicated for creditors.
• Suppliers: No direct impact is indicated for suppliers.
• Customers: No direct impact is indicated for customers.

Key Dates

Keywords

Privia Health Group, PRVA, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, David Mountcastle, EVP & Chief Financial Officer, Beneficial Ownership